Scholarlink

Purpose <p>The increasing incidence of urologic malignancy after renal transplantation (RT) has become a leading cause of recipient mortality. However, no recent analyses have been performed to identify the risk factors for post-transplant urologic malignancy (PTUM) and to evaluate the effect of PTUM on RT outcomes.</p> Materials and methods <p>This retrospective, population-based cohort study was based on Organ Procurement and Transplantation Network data.</p> Results <p>A total of 268,606 recipients underwent RT from January 2000 to December 2019 and met the inclusion criteria. Of these, 2,079 (0.77%), 1,983 (1.20% of male recipients), and 846 (0.32%) patients were diagnosed with renal cancer (RCa), prostate cancer (PCa), and bladder cancer (BCa), respectively, after RT. Urologic malignancy was a major cause of patient death after RT (RCa: 41.5%, PCa: 23.5%, BCa: 50.4%). The 5-year survival rates of the four groups ranking from best to worst were as follows: [95% confidence interval, lower value–upper value], PCa, 93.3% [92.2%–94.4%]; cancer-free, 87.2% [87.0%–87.3%]; RCa, 87.2% [85.8%–88.7%]; BCa, 81.0% [78.4%–83.7%] (<i>P</i> &lt; 0.001 for all, except cancer-free vs. RCa, <i>P</i> = 1.00).</p> Conclusions <p>The effects of PTUM on RT outcomes differ depending on the type of malignancy. Thus, a personalized approach to screening may be an appropriate strategy to address the multitude of complex issues that RT recipients encounter.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Urologic malignancy in renal transplant recipients: Analysis of OPTN/UNOS data from 2000 to 2022

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月27日

查看全文
  • Xiaowei Hao,
  • Chenxi Ye,
  • Wenhui Lai,
  • Junnan Xu,
  • Yangyang Wu,
  • Yi Sun,
  • Haigang Pang,
  • Chao Lv,
  • Kaikai Lv,
  • Guorong Yang,
  • Jie Wang,
  • Yang Gao,
  • Yin Lu,
  • Shuai Huang,
  • Zhenjun Luo,
  • Jun Dong,
  • Mingxing Zhao,
  • Xu Zhang,
  • Huaizhou Chen,
  • Qing Yuan

摘要

Purpose

The increasing incidence of urologic malignancy after renal transplantation (RT) has become a leading cause of recipient mortality. However, no recent analyses have been performed to identify the risk factors for post-transplant urologic malignancy (PTUM) and to evaluate the effect of PTUM on RT outcomes.

Materials and methods

This retrospective, population-based cohort study was based on Organ Procurement and Transplantation Network data.

Results

A total of 268,606 recipients underwent RT from January 2000 to December 2019 and met the inclusion criteria. Of these, 2,079 (0.77%), 1,983 (1.20% of male recipients), and 846 (0.32%) patients were diagnosed with renal cancer (RCa), prostate cancer (PCa), and bladder cancer (BCa), respectively, after RT. Urologic malignancy was a major cause of patient death after RT (RCa: 41.5%, PCa: 23.5%, BCa: 50.4%). The 5-year survival rates of the four groups ranking from best to worst were as follows: [95% confidence interval, lower value–upper value], PCa, 93.3% [92.2%–94.4%]; cancer-free, 87.2% [87.0%–87.3%]; RCa, 87.2% [85.8%–88.7%]; BCa, 81.0% [78.4%–83.7%] (P < 0.001 for all, except cancer-free vs. RCa, P = 1.00).

Conclusions

The effects of PTUM on RT outcomes differ depending on the type of malignancy. Thus, a personalized approach to screening may be an appropriate strategy to address the multitude of complex issues that RT recipients encounter.